Pierre Fabre Laboratories and Vernalis announce a collaboration for the study and development of oncological drugs
CASTRES, France and CAMBRIDGE, United Kingdom, September 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (I D) Ltd ("Vernalis"), a wholly owned subsidiary of HitGen Inc, are pleased to announce a long-term partnership deadline to identify preclinical candidates against multiple oncological targets.
Under the terms of the agreement, Vernalis will leverage its expertise to further study and develop drugs against an undisclosed portfolio of targets and use fragment- and structure-based methods to identify small molecules that modulate their activity. This research will be combined with Pierre Fabre Laboratories' oncology expertise to identify drug candidates for the treatment of various types of cancer, with a view to their further development and commercialization by Pierre Fabre Laboratories. Research at Vernalis will be funded by Pierre Fabre Laboratories, which will also take care of clinical and research milestones and royalties on marketed products. Detailed terms of the agreement have been disclosed.
James Murray, Chief Research Officer of Vernalis, said: "This strategic partnership builds on Vernalis' track record of innovation and success in the study and development of drugs and the identification of clinical candidates for a wide variety of therapeutic targets. We look forward to building this long-term partnership with Pierre Fabre Laboratories, leveraging their deep expertise in cancer biology and clinical development."
Francesco Hofmann, Director of Healthcare R&D at Pierre Fabre Laboratories: "The partnership with Vernalis represents an important milestone for us. Leveraging their expertise in key areas of structure-based drug design to deliver high-quality clinical candidates across multiple oncology targets." "is a real asset to develop our small molecule drug study and development project."
About Pierre Fabre LaboratoriesPierre Fabre Laboratories is a leading French medical and care company with 4 decades of experience in innovation, development, manufacturing and marketing in the oncology sector. The company dedicated nearly 80% of its R&D spending to oncology in 2022 and has declared targeted therapies as its top R&D priority. Its current commercial portfolio in oncology spans colorectal, breast and lung cancers, melanoma , hematology and precancerous skin conditions such as actinic keratosis.
In 2022, Pierre Fabre Laboratories had a turnover of €2.7 billion, 69% of which came from international sales in 120 countries. Established in the south-west of France since its creation in 1962, the Group manufactures more than 90% of its products in France and employs around 9,600 people worldwide. The company is 86% owned by the Pierre Fabre Foundation, a public interest foundation recognized by the government, and secondarily by its own employees through an international employee share plan. Pierre Fabre Laboratories' sustainability policy has been evaluated by the certification body AFNOR at the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development).
More information about Pierre Fabre Laboratories can be found at www.pierre-fabre.com, @PierreFabre.
About Vernalis
For more information about Vernalis, visit: www.vernalis.com
MEDIA CONTACTS:
Pierre Fabre Laboratories: Laure Sgandurralaure.sgandurra@pierre-fabre.com
Logo - https://mma.prnewswire.com/media/2217547...
View original content: https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-y-vernalis-anuncian-colaboracion-301934933.html
